scholarly journals High-Sensitivity Troponin in the Triage of Acute Decompensated Heart Failure ∗

2016 ◽  
Vol 4 (7) ◽  
pp. 600-602 ◽  
Author(s):  
Allan S. Jaffe ◽  
David A. Morrow ◽  
Benjamin M. Scirica
Keyword(s):  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
High Sensitivity ◽  
Decompensated Heart Failure ◽  
High Sensitivity Troponin

High-Sensitivity Troponin T and Chance of Survival in Acute Decompensated Heart Failure

2016 ◽  
Vol 22 (9) ◽  
pp. S176
Author(s):  
Keigo Hattori ◽  
Makoto Suzuki ◽  
Atsushi Seki ◽  
Yuji Nagatomo ◽  
Tetsuya Tobaru ◽  
...  
Keyword(s):  
Heart Failure ◽  
Troponin T ◽  
Acute Decompensated Heart Failure ◽  
High Sensitivity ◽  
Decompensated Heart Failure ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T

scholarly journals Biomarkers In Acute Heart Failure — Cardiac And Kidney

2015 ◽  
Vol 1 (2) ◽  
pp. 107 ◽  
Author(s):  
A Mark Richards ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Test Performance ◽  
Acute Decompensated Heart Failure ◽  
Unmet Need ◽  
Kidney Injury ◽  
High Sensitivity ◽  
Decompensated Heart Failure ◽  
Predictive Values

Natriuretic peptides (NP) are well-validated aids in the diagnosis of acute decompensated heart failure (ADHF). In acute presentations, both brain natriuretic peptide (BNP) and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) offer high sensitivity (>90 %) and negative predictive values (>95 %) for ruling out ADHF at thresholds of 100 and 300 pg/ml, respectively. Plasma NP rise with age. For added rule-in performance age-adjusted thresholds (450 pg/ml for under 50 years, 900 pg/ml for 50—75 years and 1,800 pg/ml for those >75 years) can be applied to NT-proBNP results. Test performance (specificity and accuracy but not sensitivity) is clearly reduced by renal dysfunction and atrial fibrillation. Obesity offsets the threshold downwards (to ~50 pg/ml for BNP), but overall discrimination is preserved. Reliable markers for impending acute kidney injury in ADHF constitute an unmet need, with candidates, such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, failing to perform sufficiently well, and new possibilities, including the cell cycle markers insulin growth factor binding protein 7 and tissue inhibitor of metalloproteinases type 2, remain the subject of research.

scholarly journals Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial

2019 ◽  
Vol 40 (40) ◽  
pp. 3345-3352 ◽  
Author(s):  
David A Morrow ◽  
Eric J Velazquez ◽  
Adam D DeVore ◽  
Margaret F Prescott ◽  
Carol I Duffy ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Decompensated Heart Failure ◽  
High Sensitivity ◽  
Decompensated Heart Failure ◽  
Cardiovascular Death ◽  
Double Blind ◽  
Reduced Ejection Fraction ◽  
Treatment Groups ◽  
Myocardial Stress ◽  
Patients With Heart Failure

Abstract Aims Circulating high-sensitivity cardiac troponin (hsTn) and soluble ST2 (sST2) reflect myocardial stress in patients with heart failure (HF). Production of cyclic guanosine 3′5′ monophosphate (cGMP) in response to activation of natriuretic peptide receptors reduces cardiac afterload and preload. We assessed the effects of sacubitril/valsartan on these biomarkers in patients with reduced ejection fraction and acute decompensated HF (ADHF). Methods and results PIONEER-HF was a randomized, double-blind trial of sacubitril/valsartan vs. enalapril in hospitalized patients with ADHF following haemodynamic stabilization. We measured circulating hsTnT, sST2, and urinary cGMP at baseline, 1, 2 (sST2, cGMP), 4, and 8 weeks (n = 694 with all baseline biomarkers). Ratios of geometric means (timepoint/baseline) were determined and compared as a ratio for sacubitril/valsartan vs. enalapril. Compared with enalapril, sacubitril/valsartan led to a significantly greater decline in hsTnT and sST2. This effect emerged as early as 1 week for sST2 and was significant for both at 4 weeks with a 16% greater reduction in hsTnT (P < 0.001) and 9% greater reduction in sST2 (P = 0.0033). Serial urinary cGMP increased with sacubitril/valsartan compared with enalapril (P < 0.001, 1 week). The significant differences between treatment groups for each biomarker were sustained at 8 weeks. In an exploratory multivariable-adjusted analysis of cardiovascular death or HF-rehospitalization, the concentrations of hsTnT, sST2 at week 1 were significantly associated with subsequent outcome. Conclusion Biomarkers of myocardial stress are elevated in patients with ADHF and associated with outcome. Compared with enalapril, sacubitril/valsartan reduces myocardial injury and haemodynamic stress as reflected by biomarkers, with an onset that is apparent within 1–4 weeks. Clinical trials registration NCT 02554890 clinical.trials.gov

Troponin T, but not high-sensitivity C-reactive protein, predicts outcomes in patients hospitalized with acute decompensated heart failure

2003 ◽  
Vol 9 (5) ◽  
pp. S90 ◽  
Author(s):  
Maria I. Sosa Liprandi ◽  
Alvaro Sosa Liprandi ◽  
Alejandro Barbagelata ◽  
Marta Garcia Ben ◽  
Claudia Latorraga ◽  
...  
Keyword(s):  
Heart Failure ◽  
Troponin T ◽  
Acute Decompensated Heart Failure ◽  
High Sensitivity ◽  
Decompensated Heart Failure ◽  
C Reactive Protein ◽  
Reactive Protein
Sign in / Sign up

Export Citation Format

Share Document